Buyback12 Mar 2026, 02:31 pm
Jagsonpal Pharmaceuticals Announces Buyback of Equity Shares at 250, a 40% Premium
AI Summary
Jagsonpal Pharmaceuticals Limited has approved a proposal to buyback up to 16,00,000 fully paid-up equity shares at a price of 250, a premium of 40% to the current market price. The total consideration for the buyback is X 40 crores. The promoters will not participate in the buyback. The company intends to use a blend of equity and debt for any inorganic growth opportunity. The proposed buyback is expected to lead to a 400 bps improvement in ROCE.
Key Highlights
- Buyback of up to 16,00,000 equity shares at a price of 250
- Premium of 40% to the current market price
- Total consideration of X 40 crores
- Promoters not participating in the buyback
- Intended use of blend of equity and debt for inorganic growth opportunities
- Expected 400 bps improvement in ROCE